-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Cbmhb0dYnpQASU5p5drz7n0SpYqYxN2VQUlnlb7XuQNDpGru07+0x6tU12CFp6Bc TNX1aDMamYvr8ShSEnDv7g== /in/edgar/work/20000619/0000950115-00-000836/0000950115-00-000836.txt : 20000920 0000950115-00-000836.hdr.sgml : 20000919 ACCESSION NUMBER: 0000950115-00-000836 CONFORMED SUBMISSION TYPE: POS AM PUBLIC DOCUMENT COUNT: 1 REFERENCES 429: 333-82667 FILED AS OF DATE: 20000619 FILER: COMPANY DATA: COMPANY CONFORMED NAME: GENEREX BIOTECHNOLOGY CORP CENTRAL INDEX KEY: 0001059784 STANDARD INDUSTRIAL CLASSIFICATION: [2834 ] IRS NUMBER: 820490211 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: POS AM SEC ACT: SEC FILE NUMBER: 333-82667 FILM NUMBER: 657085 BUSINESS ADDRESS: STREET 1: 33 HARBOUR SQ STREET 2: STE 202 CITY: TORONTO ONTARIO CANA STATE: A1 BUSINESS PHONE: 4163642551 MAIL ADDRESS: STREET 1: 33 HARBOUR SQ STREET 2: STE 202 CITY: TORONTO ONTARIO M5J STATE: A1 POS AM 1 0001.txt POST-EFFECTIVE AMENDMENT REGISTRATION NO. 333-82667 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ------------------------- FORM S-1/A Post-effective Amendment No. 1 ------------------------- GENEREX BIOTECHNOLOGY CORPORATION (Name of Issuer in Its Charter) Delaware 2834 82-0490211 (State or jurisdiction of (Primary Standard Industrial (I.R.S. Employer incorporation or organization) Classification Code Number) Identification No.)
33 Harbour Square, Suite 202 Toronto, Ontario CANADA M5J 2G2 Telephone: 416/364-2551 Facsimile: 416/364-9363 Anna E. Gluskin, CEO and President 33 Harbour Square, Suite 202 Toronto, Ontario CANADA M5J 2G2 Telephone: 416/364-2551 Facsimile: 416/364-9363 (Name, address and telephone number of agent for service) ------------------------- Copies to: Joseph Chicco, Esquire Eckert Seamans Cherin & Mellott, LLC 1515 Market Street - 9th Floor Philadelphia, PA 19102 Telephone: 215/851-8410 Facsimile: 215/851-8383 ------------------------- Approximate date of commencement of proposed sale to the public: November 19, 1999 If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the box. [x] If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering [ ] If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. [ ] If delivery of the prospectus is expected to be made pursuant to Rule 434, please check the following box. [ ] REMOVAL FROM REGISTRATION Pursuant to the undertaking set forth in Item 27 of this Registration Statement, Generex Biotechnology Corporation (the "Registrant") hereby removes from registration under the Registration Statement all securities registered hereby that remain unsold. SIGNATURES In accordance with the requirements of the Securities Act of 1933, we certify that we have authorized this Post-effective Amendment to the Registration Statement to be signed on our behalf by the undersigned, our President, on the 13th day of June, 2000. GENEREX BIOTECHNOLOGY CORPORATION By: /s/ Anna E. Gluskin -------------------------- Anna E. Gluskin, President SIGNATURES In accordance with the requirements of the Securities Act of 1933, this Post-effective Amendment to the Registration Statement was signed by the following persons in the capacities and on the dates stated.
Signatures Title Date - ---------- ----- ---- /s/ Anna E. Gluskin - ------------------- Anna E. Gluskin President, Chief Executive Officer and June 13, 2000 Director /s/ E. Mark Perri - ------------------- E. Mark Perri Chairman of the Board, Chief Financial June 13, 2000 Officer and Director /s/ Rose C. Perri - ------------------- Rose C. Perri Director June 13, 2000 /s/ Pankaj Modi - ------------------- Pankaj Modi, Ph.D. Director June 13, 2000
-----END PRIVACY-ENHANCED MESSAGE-----